Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by KayakerBCon Oct 26, 2015 7:43pm

267 Views

Post# 24228879

RE:RE:RE:RE: News Release Issued: Oct 26, 2015 (5:00am MDT) Resverlogix

Looking back at how ASSURE progressed, I think data analysis/results for BETonMACE will probably take only 2-3 months. As late as 2012 09 19, Anticipated Primary Completion Date for ASSURE was listed as 2012-11. The Actual date ended up being 2013 05. Assuming similar slippage, the estimate for release of BETonMACE results I see would be mid 2019.

Bullboard Posts

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload